Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 - Seite 2

Location:
Date & Time:
Speaker: 1433
Hall B4-5
4/7/24, 1:15 – 2:00 PM ET
Harold Bays, MD, FOMA, FTOS, FACC, FNLA, FASPC; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, Kentucky     Moderated Presentation Title:   
Session:         
Location:        
Date & Time:              Speaker:          Impact of Payer Rejections and Out-Of-Pocket Costs on Patient Access to Bempedoic Acid Therapy 
1092
Moderated Poster Theatre 08
4/7/24, 3:15 – 3:25 PM ET
Jimin Hwang, MD; UT Southwestern Medical Center, Dallas, Texas     Industry Expert Theatre Title:                          
Location:                    
Date & Time: Speaker:          A Next Step in Cardiovascular Disease Management
Theatre #2
4/7/2024, 11:15 AM – 12:15 PM ET
Manesh Patel, MD Chief, Division of Cardiology, Director Duke Heart Center

Esperion Therapeutics

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.